L-Nio dihydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Nio dihydrochloride
• 英文别名: (2S)-2-amino-5-(1-aminoethylideneamino)pentanoic acid;dihydrochloride
• 化学式: C7H17Cl2N3O2
• 分子量: 246.13
• InChiKey: RYCMAAFECCXGHI-ILKKLZGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  102
• 氢给体数：
  5
• 氢受体数：
  4

文献信息

• SYNTHESIS AND USE OF NOVEL INHIBITORS AND INACTIVATORS OF PROTEIN ARGININE DEIMINASES
  申请人：Thompson Paul Ryan

  公开号：US20090306153A1

  公开（公告）日：2009-12-10

  In one embodiment of the present disclosure, an inactivator of protein arginine deiminase 4 is disclosed. The inactivator includes: (I) and x includes F; Cl, and H, y includes OH and NH 2 , R includes H, an alkyl group, an alkenyl group, an alknyl group, and n is greater than 0.

  在本公开的一种实施例中，揭示了一种蛋白质精氨酸脱亚胺酶4的失活剂。该失活剂包括：（I）和x包括F、Cl和H，y包括OH和NH2，R包括H、烷基、烯基、炔基，n大于0。
• Methods of treating hepatitis
  申请人：——

  公开号：US20040052866A1

  公开（公告）日：2004-03-18

  The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

  本发明涉及一种治疗患者肝炎的方法，其中包括向患者施用包含一氧化碳的药物组合物。
• Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
  申请人：——

  公开号：US20040131703A1

  公开（公告）日：2004-07-08

  The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

  本发明涉及利用一氧化氮（NO）、血红素加氧酶-1（HO-1）和血红素降解产物（如一氧化碳（CO）、胆红素、胆红素和铁）治疗疾病。
• Method of treatment of endothelial dysfunction and engineered proteins for same
  申请人：Price M. Elmer

  公开号：US20050074448A1

  公开（公告）日：2005-04-07

  Endothelial cells produce many factors that are involved in maintaining blood vessels. One of the best understood and most studied factor is nitric oxide (NO), which is produced by an endothelial enzyme called nitric oxide synthase (eNOS). The present invention provides a molecule designed to be delivered to the endothelium where it can reconstitute eNOS activity and restore NO production. Thus, the present invention provides methods of detecting, treating and preventing diseases or disorders associated with the vasculature and denoted by reduced levels of eNOS in the endothelium, as well as a concomitant reduction in the amount of NO that can be produced.

  内皮细胞会产生许多参与维护血管的因子。一氧化氮（NO）是最容易理解和研究的因子之一，它是由一种叫做一氧化氮合酶（eNOS）的内皮酶产生的。本发明提供了一种可输送到内皮细胞的分子，它可以重建 eNOS 的活性并恢复 NO 的产生。因此，本发明提供了检测、治疗和预防与血管有关的疾病或失调的方法，这些疾病或失调表现为内皮细胞中的 eNOS 水平降低，以及可产生的 NO 量随之减少。
• METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
  申请人：EyePoint Pharmaceuticals, Inc.

  公开号：EP3956021A1

  公开（公告）日：2022-02-23